Skip to Content

Clinical Trials

Diabetes Research Registry
Aims: The purpose of the registry is to collect clinical information related to diabetes for researchers to study and learn more about diabetes. Additionally, the registry is being created to inform participants of ongoing and future diabetes related studies which they may be eligible to participate in.
Diagnosis: Any type of diabetes (type 1, type 2, gestational, etc.)
Principal Investigator: Liana Billings, MD
IRB Approval Number: EH15-309
Sponsor: N/A
Contact: Interested patients may contact diabetes research staff at 847.663.8510 or email diabetesresearch@northshore.org
Open to Enrollment: Yes

Patients with Hyperglycemia Assessed for Response to Medications by Genetics (PHARMGen)
Aims: The purpose of this study is to look at how well diabetes medications work depending on an individual’s genetic makeup. We will examine the genetic variants that you were born with and see how these influence how well you respond to anti-diabetes medication. This could greatly improve diabetes treatment in the future by allowing doctors to personalize medications to individual needs.
Diagnosis: Type 2 diabetes
Principal Investigator: Liana Billings, MD
IRB Approval Number: EH14-159
Sponsor: N/A
Contact: Interested patients may contact diabetes research staff at 847.663.8510 or email diabetesresearch@northshore.org
Open to Enrollment: Yes

Find MODY - A Study to FIND Individuals with Maturity-onset Diabetes of the Young (MODY) Who Have Been Misdiagnosed as Type 1 or Type 2 Diabetes
Aims: This is a 3-phase study to FIND individuals with Maturity-onset Diabetes of the Young (MODY) who have been misdiagnosed as Type 1 or Type 2 Diabetes and implement gene-directed pharmacotherapies as well as identify new causal mutations and medical therapies. Currently, the study is in phase I where researchers are using the electronic medical record to identify and characterize individuals who are high risk for MODY. Phase II will be started once phase I is completed. Patients identified at high risk from phase I will be contacted to fill out a genetic survey, complete laboratory testing, and obtain genetic testing for MODY.
Diagnosis: Type 1 and Type 2
Principal Investigator: Liana Billings, MD
IRB Approval Number: EH14-424
Sponsor: N/A
Contact: For the FIND MODY trial we will contact participants who qualify.  If you believe you may be at risk of having  MODY or neonatal diabetes, please contact diabetes research staff at 847.663.8510 or email diabetesresearch@northshore.org. We can make arrangements for you to be evaluated in the Personalized Medicine in Diabetes Consultation Clinic.
Open to Enrollment: Yes

DUAL™ IX - A clinical trail comparing glycemic control and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine (IGlar) as add-on therapy to SGLT2i in subjects with type 2 diabetes mellitus
Aims: The purpose of the study is to compare two different combinations of anti-diabetes medications for managing blood glucose in patient with type 2 diabetes. The study will place eligible participants on either lantus, SGLT2i, and oral anti-diabetes medication such as metformin or insulin degludec/liraglutide (IDegLira), SGLT2i, and oral anti-diabetes medication such as metformin therapy. IDegLira is considered an investigational by the Food and Drug Administration for type 2 diabetes.
Diagnosis: Type 2 diabetes
Principal Investigator: Liana Billings, MD
Sponsor: Novo Nordisk
Contact: Interested patients may contact Cheryl Auston, RN at 847.663.8524, causton@northshore.org
Open to Enrollment: Yes

DUAL™ VII - Insulin Degludec/Liraglutide (IDegLira) vs. Basal-bolus Therapy: A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects with Type 2 Diabetes
Aims: The purpose of the study is to compare two different combinations of anti-diabetes medications for managing blood glucose in patient with type 2 diabetes. The study will place eligible participants on either metformin, lantus, and novolog or metformin and insulin degludec/liraglutide (IDegLira) therapy. IDegLira is considered an investigational by the Food and Drug Administration for type 2 diabetes.
Diagnosis: Type 2 diabetes
Principal Investigator: Liana Billings, MD
Sponsor: Novo Nordisk
Contact: Interested patients may contact Cheryl Auston, RN at 847.663.8524, causton@northshore.org
Open to Enrollment: No

Multiple Daily Injection and Continuous glucose Monitoring in Diabetes: DIaMonD Study
Aims: The purpose of this study is to look at the potential benefits of improving blood glucose (sugar) levels through a use of the Dexcom G4 PLATINUM continuous glucose monitor (CGM) compared to the use of a blood glucose meter. Eligible patients will be randomized to receive either the CGM or continue current diabetes care with a blood glucose meter.
Diagnosis: Type 2 diabetes
Principal Investigator: Liana Billings, MD
IRB Approval Number: EH15-380
Sponsor: Dexcom
Contact: Interested patients may contact Cheryl Auston, RN at 847.663.8524, causton@northshore.org
Open to Enrollment: No